In addition, we detected other mutations in CRC patients that are known to participate in the EGFR-signaling pathway, such as ERBB2 (c.922G>A, c.2690G>A), and EGFR (c.2116C>T and c.630G>A). This evidence concerns the gene ERBB2 and colorectal carcinoma.